Overview
Pure EPA reduces residual cardiovascular risk on statins.
- Endogenously produced or biosynthesized molecule
- Standardized pharmaceutical- or food-grade supplement
- Combined with cofactors that improve absorption or activity
- Capsule or softgel
- Powder
- Sublingual or buccal
- Liposomal liquid
Forms & variants of Omega-3 (EPA/DHA)
Different chemical forms of Omega-3 (EPA/DHA) behave differently. Browse each form's mechanism, bioavailability, and best-use context.
Mechanism of action
Lowers triglycerides via PPAR-α activation and reduces vascular inflammation.
- · Lowers triglycerides via PPAR-α activation
- · reduces vascular inflammation
Effects on the body
Organ system effects
EPA-Only Omega-3 supports endothelial function, lipid profile, or blood-pressure regulation in cardiovascular trials.
EPA-Only Omega-3 modulates monoaminergic and GABAergic tone relevant to mood and anxiety regulation.
Evidence-based benefits
Reduces major CV events in high-risk patients (REDUCE-IT)
Strong evidencePotential side effects
- · Fishy aftertaste
- · Bleeding tendency
- · Atrial fibrillation
Drug interactions
Supplement interactions
- Omega-3Anti-inflammatory cardiovascular synergy.
- CoQ10Supports mitochondrial energetics in cardiac tissue.
No specific avoidances listed.
Dosing & bioavailability
Where to buy
Affiliate links — we may earn a commission at no extra cost to you. Amazon code supplementsch-20 is auto-applied at checkout. We don't endorse specific brands; verify third-party testing (USP, NSF, Informed Sport) before purchase.
Scientific evidence8Show studiesHide studies
REDUCE-IT trial
Bhatt DL, et al.
5-year DB-RCT in 8179 high-risk patients on statins.
4 g/day icosapent ethyl reduced MACE by 25%.
PubMed: EPA-Only Omega-3 — Reduces major CV events in high-risk patients
Live PubMed search
Live results for "EPA-Only Omega-3 Reduces major CV events in high-risk patients" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "Reduces major CV events in high-risk patients". Filter by RCT, meta-analysis, or year on the results page.
PubMed: EPA-Only Omega-3 — randomized controlled trial
Live PubMed search
Live results for "EPA-Only Omega-3 randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.
PubMed: EPA-Only Omega-3 — meta-analysis
Live PubMed search
Live results for "EPA-Only Omega-3 meta-analysis" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.
PubMed: EPA-Only Omega-3 — pharmacokinetics
Live PubMed search
Live results for "EPA-Only Omega-3 pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.
PubMed: EPA-Only Omega-3 — safety adverse events
Live PubMed search
Live results for "EPA-Only Omega-3 safety adverse events" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.
PubMed: EPA-Only Omega-3 — dose response
Live PubMed search
Live results for "EPA-Only Omega-3 dose response" across the PubMed/MEDLINE peer-reviewed index.
Opens current human and preclinical literature matching EPA-Only Omega-3 and "dose response". Filter by RCT, meta-analysis, or year on the results page.
Google Scholar: EPA-Only Omega-3 — clinical evidence
Live Scholar search
Cross-database citation index for EPA-Only Omega-3 as it relates to "clinical evidence".
Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.